Senior Medical Director, Italy
Pubblicato il 24-09-2026 - Acadia Pharmaceuticals in Milano
About Acadia Pharmaceuticals
Se sta pensando di inviare una candidatura, si ricordi di premere il pulsante apposito dopo aver letto l'intera descrizione.
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference.
Role Overview
The (Senior) Medical Director, Italy will serve as the foundational medical leader for Rett syndrome in Italy, responsible for designing and executing the full pre-launch and launch medical strategy for a first commercial product, in close collaboration with the country medical staff and aligned with Regional medical and country launch readiness plan strategy. This role combines strategic leadership with hands-on execution, requiring comfort operating with limited infrastructure, evolving processes, and high ambigu